Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBT (2016 - 2025)

Historic EBT for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.

  • CytomX Therapeutics' EBT fell 34445.4% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 8766.93%. This contributed to the annual value of $32.1 million for FY2024, which is 86578.39% up from last year.
  • As of Q3 2025, CytomX Therapeutics' EBT stood at -$14.2 million, which was down 34445.4% from -$91000.0 recorded in Q2 2025.
  • CytomX Therapeutics' EBT's 5-year high stood at $23.6 million during Q1 2025, with a 5-year trough of -$34.8 million in Q4 2021.
  • For the 5-year period, CytomX Therapeutics' EBT averaged around -$9.0 million, with its median value being -$6.5 million (2024).
  • Within the past 5 years, the most significant YoY rise in CytomX Therapeutics' EBT was 89359.92% (2024), while the steepest drop was 49641.21% (2024).
  • CytomX Therapeutics' EBT (Quarter) stood at -$34.8 million in 2021, then skyrocketed by 74.8% to -$8.8 million in 2022, then soared by 121.72% to $1.9 million in 2023, then soared by 893.6% to $18.9 million in 2024, then crashed by 174.83% to -$14.2 million in 2025.
  • Its EBT stands at -$14.2 million for Q3 2025, versus -$91000.0 for Q2 2025 and $23.6 million for Q1 2025.